Stock Analysis

CareRay Digital Medical Technology Second Quarter 2024 Earnings: EPS: CN¥0.093 (vs CN¥0.063 in 2Q 2023)

Published
SHSE:688607

CareRay Digital Medical Technology (SHSE:688607) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥75.9m (up 25% from 2Q 2023).
  • Net income: CN¥6.15m (up 10% from 2Q 2023).
  • Profit margin: 8.1% (down from 9.2% in 2Q 2023). The decrease in margin was driven by higher expenses.
  • EPS: CN¥0.093 (up from CN¥0.063 in 2Q 2023).
SHSE:688607 Earnings and Revenue Growth August 25th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

CareRay Digital Medical Technology Earnings Insights

Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China.

Performance of the Chinese Medical Equipment industry.

The company's shares are down 9.0% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on CareRay Digital Medical Technology's balance sheet.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.